- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00533611
Effect of MK0524A on Flushing Caused by Niacin (0524A-056)
February 16, 2017 updated by: Merck Sharp & Dohme LLC
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Tolerability and Effect of MK0524A on Niacin-Induced Acute Flushing in Lipid Clinic Patients
The primary objective of the study is to assess the effects of MK0524A in reducing flushing associated with niacin.
Study Overview
Status
Completed
Conditions
Study Type
Interventional
Enrollment
330
Phase
- Phase 3
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patient is male or female between 18 and 70 years of age
- Females of reproductive potential must agree to take acceptable contraceptive precautions for the duration of the study
Exclusion Criteria:
- Patient has a history of hypersensitivity to niacin or niacin-containing products
- Patient is currently experiencing menopausal hot flashes
- Patient consumes more than 2 alcoholic beverages per day
- Patient has poorly controlled Type 1 or Type 2 diabetes mellitus
- Patient engages in vigorous exercise or an aggressive diet regimen
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
MK-0524A produces less flushing during the acute dosing period than niacin extended-release as measured by maximum Global Flushing Severity Score (GFSS) categorized as none/mild, moderate, severe, extreme.
Time Frame: Over 1 week
|
Over 1 week
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
MK-0524A produces less flushing during the acute dosing period than niacin extended-release as measured by (a) maximum daily GFSS; and (b) percentage of patients with a maximum GFSS =4 (moderate or greater).
Time Frame: Daily
|
Daily
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2007
Primary Completion (Actual)
August 1, 2007
Study Completion (Actual)
August 1, 2007
Study Registration Dates
First Submitted
September 19, 2007
First Submitted That Met QC Criteria
September 19, 2007
First Posted (Estimate)
September 21, 2007
Study Record Updates
Last Update Posted (Actual)
February 17, 2017
Last Update Submitted That Met QC Criteria
February 16, 2017
Last Verified
February 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 0524A-056
- MK0524A-056
- 2007_604
Plan for Individual participant data (IPD)
Study Data/Documents
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Flushing
-
University Hospital Inselspital, BerneRecruitingPostmenopausal | Postmenopausal FlushingSwitzerland
-
Imperial College LondonAstraZeneca; Medical Research Council; National Institute for Health Research...CompletedMenopausal FlushingUnited Kingdom
-
Northwestern UniversityActive, not recruiting
-
Rio de Janeiro State UniversityCompletedEndothelial Dysfunction | Cardiovascular Risk Factor | Postmenopausal FlushingBrazil
-
Skin Laser & Surgery SpecialistsGalderma R&DTerminatedErythema and Flushing Associated With Rosacea
-
Eastern Virginia Medical SchoolAbbottCompleted
-
University of PennsylvaniaAbbottCompleted
Clinical Trials on MK0524A, /Duration of Treatment : 4 Weeks
-
Merck Sharp & Dohme LLCCompletedHypercholesterolemia
-
H. Lundbeck A/STerminated
-
Merck Sharp & Dohme LLCCompleted
-
Organon and CoCompleted
-
Organon and CoCompleted
-
Organon and CoCompletedHypercholesterolemia
-
Organon and CoCompletedChronic Low Back Pain
-
Organon and CoCompleted